A Phase I study of 'Tomudex' and gemcitabine in advanced cancer

被引：1
|
作者：
Cripps, C
Batist, G
Dahrouge, S
Fry, D
McQuillan, A
Kolendowicz, R
Abugaber, AA
机构：
[1] Ottawa Reg Canc Ctr, Ottawa, ON K1Y 4K7, Canada
[2] Jewish Gen Hosp, Clin Res Unit, Quebec City, PQ, Canada
来源：
EUROPEAN JOURNAL OF CANCER | 1999年 / 35卷
关键词：
D O I：
10.1016/S0959-8049(99)81582-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1162
引用
收藏
页码：S289 / S289
页数：1
相关论文
共 50 条
  • [31] Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer
    Kim, R. D.
    Alberts, S. R.
    Pena, C.
    Genvresse, I.
    Ajavon-Hartmann, A.
    Xia, C.
    Kelly, A.
    Grilley-Olson, J. E.
    BRITISH JOURNAL OF CANCER, 2018, 118 (04) : 462 - 470
  • [32] Phase I study of nab-paclitaxel and gemcitabine combination in patients with advanced pancreatic cancer
    Drengler, R. L.
    Smith, L. S.
    Wood, T. E.
    Borad, M. J.
    Ramanathan, R. K.
    Laheru, D. A.
    Hidalgo, M.
    Von Hoff, D. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [33] A phase-I study of the combination of intravenous reovirus (REOLYSIN ®) and gemcitabine in patients with advanced cancer
    Lolkema, M. P.
    Harrington, K.
    Evans, J.
    Arkenau, H. T.
    Roxburgh, P.
    Morrison, R.
    Roulstone, V.
    Coffey, M.
    Mettinger, K.
    de Bono, J.
    EJC SUPPLEMENTS, 2009, 7 (02): : 131 - 131
  • [34] Erlotinib, gemcitabine, paclitaxel and radiation for locally advanced pancreatic cancer: A phase I study.
    Iannitti, D
    Dipetrillo, T
    Cruff, D
    Sambandam, S
    Maia, C
    Hughes, M
    Oldenburg, N
    Thornton, K
    Kennedy, T
    Safran, H
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 336S - 336S
  • [35] Phase I study of combination of pasireotide LAR + gemcitabine in locally advanced or metastatic pancreatic cancer
    Yaman Suleiman
    Amit Mahipal
    David Shibata
    Erin M. Siegel
    Helen Jump
    William J. Fulp
    Gregory M. Springett
    Richard Kim
    Cancer Chemotherapy and Pharmacology, 2015, 76 : 481 - 487
  • [36] Phase I and pharmacokinetic study of the differentiating agent vesnarinone in combination with gemcitabine in patients with advanced cancer
    Patnaik, A
    Rowinsky, EK
    Tammara, BK
    Hidalgo, M
    Drengler, RL
    Garner, AM
    Siu, LL
    Hammond, LA
    Felton, SA
    Mallikaarjun, S
    Von Hoff, DD
    Eckhardt, SG
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (23) : 3974 - 3985
  • [37] Raltitrexed (Tomudex™) plus doxorubicin (DOX) in patients with advanced gastric cancer:: Interim results of a phase I dose escalation study
    Bjarnason, G
    Charpentier, D
    Winquist, E
    Wong, R
    Matthews, S
    Seymour, L
    ANNALS OF ONCOLOGY, 1998, 9 : 120 - 120
  • [38] Phase I and pharmacokinetic study of Tomudex combined with 5-fluorouracil plus levofolinic acid in advanced head and neck cancer and colorectal cancer
    Caponigro, F
    Avallone, A
    McLeod, H
    Cartenì, G
    De Vita, F
    Casaretti, R
    Morsman, J
    Blackie, R
    Budillon, A
    De Lucia, L
    Gravina, A
    Catalano, G
    Comella, P
    Comella, G
    CLINICAL CANCER RESEARCH, 1999, 5 (12) : 3948 - 3955
  • [39] Phase II study of gemcitabine in patients with advanced pancreatic cancer
    Carmichael, J
    Fink, U
    Russell, RCG
    Spittle, MF
    Harris, AL
    Spiessi, G
    Blatter, J
    BRITISH JOURNAL OF CANCER, 1996, 73 (01) : 101 - 105
  • [40] Gemcitabine: A phase II study in patients with advanced renal cancer
    DeMulder, PHM
    Weissbach, L
    Jakse, G
    Osieka, R
    Blatter, J
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1996, 37 (05) : 491 - 495
12345